COLL Relative Valuation
COLL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, COLL is overvalued; if below, it's undervalued.
Historical Valuation
Collegium Pharmaceutical Inc (COLL) is now in the Undervalued zone, suggesting that its current forward PE ratio of 6.01 is considered Undervalued compared with the five-year average of 4.68. The fair price of Collegium Pharmaceutical Inc (COLL) is between 102.00 to 114.75 according to relative valuation methord. Compared to the current price of 45.68 USD , Collegium Pharmaceutical Inc is Undervalued By 55.21%.
Relative Value
Fair Zone
102.00-114.75
Current Price：45.68
55.21%
Undervalued
6.01
PE
1Y
3Y
5Y
4.37
EV/EBITDA
Collegium Pharmaceutical Inc. (COLL) has a current EV/EBITDA of 4.37. The 5-year average EV/EBITDA is 3.97. The thresholds are as follows: Strongly Undervalued below 2.60, Undervalued between 2.60 and 3.28, Fairly Valued between 4.65 and 3.28, Overvalued between 4.65 and 5.34, and Strongly Overvalued above 5.34. The current Forward EV/EBITDA of 4.37 falls within the Historic Trend Line -Fairly Valued range.
10.04
EV/EBIT
Collegium Pharmaceutical Inc. (COLL) has a current EV/EBIT of 10.04. The 5-year average EV/EBIT is 9.62. The thresholds are as follows: Strongly Undervalued below 3.96, Undervalued between 3.96 and 6.79, Fairly Valued between 12.44 and 6.79, Overvalued between 12.44 and 15.27, and Strongly Overvalued above 15.27. The current Forward EV/EBIT of 10.04 falls within the Historic Trend Line -Fairly Valued range.
1.80
PS
Collegium Pharmaceutical Inc. (COLL) has a current PS of 1.80. The 5-year average PS is 1.60. The thresholds are as follows: Strongly Undervalued below 0.81, Undervalued between 0.81 and 1.20, Fairly Valued between 1.99 and 1.20, Overvalued between 1.99 and 2.38, and Strongly Overvalued above 2.38. The current Forward PS of 1.80 falls within the Historic Trend Line -Fairly Valued range.
3.64
P/OCF
Collegium Pharmaceutical Inc. (COLL) has a current P/OCF of 3.64. The 5-year average P/OCF is 3.61. The thresholds are as follows: Strongly Undervalued below 1.37, Undervalued between 1.37 and 2.49, Fairly Valued between 4.73 and 2.49, Overvalued between 4.73 and 5.84, and Strongly Overvalued above 5.84. The current Forward P/OCF of 3.64 falls within the Historic Trend Line -Fairly Valued range.
3.64
P/FCF
Collegium Pharmaceutical Inc. (COLL) has a current P/FCF of 3.64. The 5-year average P/FCF is 2.70. The thresholds are as follows: Strongly Undervalued below -2.48, Undervalued between -2.48 and 0.11, Fairly Valued between 5.29 and 0.11, Overvalued between 5.29 and 7.88, and Strongly Overvalued above 7.88. The current Forward P/FCF of 3.64 falls within the Historic Trend Line -Fairly Valued range.
Collegium Pharmaceutical Inc (COLL) has a current Price-to-Book (P/B) ratio of 5.24. Compared to its 3-year average P/B ratio of 4.68 , the current P/B ratio is approximately 11.97% higher. Relative to its 5-year average P/B ratio of 4.17, the current P/B ratio is about 25.40% higher. Collegium Pharmaceutical Inc (COLL) has a Forward Free Cash Flow (FCF) yield of approximately 20.10%. Compared to its 3-year average FCF yield of 23.21%, the current FCF yield is approximately -13.41% lower. Relative to its 5-year average FCF yield of 18.99% , the current FCF yield is about 5.86% lower.
5.24
P/B
Median3y
4.68
Median5y
4.17
20.10
FCF Yield
Median3y
23.21
Median5y
18.99
Competitors Valuation Multiple
The average P/S ratio for COLL's competitors is 110.75, providing a benchmark for relative valuation. Collegium Pharmaceutical Inc Corp (COLL) exhibits a P/S ratio of 1.80, which is -98.38% above the industry average. Given its robust revenue growth of 31.42%, this premium appears sustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of COLL increased by 42.22% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 5.86 to 15.05.
The secondary factor is the Revenue Growth, contributed 31.42%to the performance.
Overall, the performance of COLL in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
OLPX
Olaplex Holdings Inc
1.27USD
-5.93%
PRO
Pros Holdings Inc
23.25USD
0.00%
LMB
Limbach Holdings Inc
84.08USD
6.34%
TH
Target Hospitality Corp
8.13USD
0.37%
LQDT
Liquidity Services Inc
30.68USD
3.68%
ELVN
Enliven Therapeutics Inc
15.21USD
-2.12%
CSWC
Capital Southwest Corp
22.76USD
2.11%
JBI
Janus International Group Inc
6.71USD
0.90%
KFRC
Kforce Inc
31.83USD
1.60%
INOD
Innodata Inc
62.01USD
17.02%
Frequently Asked Questions
Is Collegium Pharmaceutical Inc (COLL) currently overvalued or undervalued?
Collegium Pharmaceutical Inc (COLL) is now in the Undervalued zone, suggesting that its current forward PE ratio of 6.01 is considered Undervalued compared with the five-year average of 4.68. The fair price of Collegium Pharmaceutical Inc (COLL) is between 102.00 to 114.75 according to relative valuation methord. Compared to the current price of 45.68 USD , Collegium Pharmaceutical Inc is Undervalued By 55.21% .
What is Collegium Pharmaceutical Inc (COLL) fair value?
COLL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Collegium Pharmaceutical Inc (COLL) is between 102.00 to 114.75 according to relative valuation methord.
How does COLL's valuation metrics compare to the industry average?
The average P/S ratio for COLL's competitors is 110.75, providing a benchmark for relative valuation. Collegium Pharmaceutical Inc Corp (COLL) exhibits a P/S ratio of 1.80, which is -98.38% above the industry average. Given its robust revenue growth of 31.42%, this premium appears sustainable.
What is the current P/B ratio for Collegium Pharmaceutical Inc (COLL) as of Jan 06 2026?
As of Jan 06 2026, Collegium Pharmaceutical Inc (COLL) has a P/B ratio of 5.24. This indicates that the market values COLL at 5.24 times its book value.
What is the current FCF Yield for Collegium Pharmaceutical Inc (COLL) as of Jan 06 2026?
As of Jan 06 2026, Collegium Pharmaceutical Inc (COLL) has a FCF Yield of 20.10%. This means that for every dollar of Collegium Pharmaceutical Inc’s market capitalization, the company generates 20.10 cents in free cash flow.
What is the current Forward P/E ratio for Collegium Pharmaceutical Inc (COLL) as of Jan 06 2026?
As of Jan 06 2026, Collegium Pharmaceutical Inc (COLL) has a Forward P/E ratio of 6.01. This means the market is willing to pay $6.01 for every dollar of Collegium Pharmaceutical Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Collegium Pharmaceutical Inc (COLL) as of Jan 06 2026?
As of Jan 06 2026, Collegium Pharmaceutical Inc (COLL) has a Forward P/S ratio of 1.80. This means the market is valuing COLL at $1.80 for every dollar of expected revenue over the next 12 months.